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ABSTRACT
Background: Peroxisome proliferator-activated receptor γ (PPAR-γ) has been shown to play an important role
in the control of inflammatory responses acting on macrophages, mast cells, T cells, and eosinophils. The pre-
sent study was aimed at investigating the effects of PPAR-γ agonist on nasal symptoms and eosinophil accu-
mulations in nasal mucosa by using a murine allergic rhinitis model. Furthermore, we examined the expression
of PPAR-γ in the nasal mucosa in mice.
Methods: BALBc mice were sensitized and challenged intranasally with ovalbumin. Ciglitazone, a PPAR-γ
agonist, was administered orally 6 hours before each nasal challenge.
Results: Administration of PPAR-γ agonist significantly decreased the number of nasal rubs, nasal histamine
responsiveness, serum IgE, IL-5 production from the spleen, and eosinophilic infiltration in the nasal mucosa.
Furthermore, PPAR-γ was expressed in eosinophils and epithelial cells in the nasal mucosa by immunohisto-
chemistry.
Conclusions: PPAR-γ was expressed in eosinophils and epithelial cells in the nasal mucosa. Also, the oral
administration of ciglitazone is effective in upper airway allergic inflammation in mice.
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INTRODUCTION
The prevalence of allergic rhinitis has increased in re-
cent years and appears to be at least 300% more likely
to occur in a patient with asthma.1 The vast majority
of patients with asthma have rhinitis, and rhinitis is a
major independent risk factor for asthma.2 Allergic
rhinitis has been defined as an inflammatory disease
of the nasal mucosa characterized by the following
symptoms: nasal obstruction, sneezing, and rhinor-
rhea. Eosinophils are prominent in nasal washings,
smears, and biopsies of the nasal mucosa in patients
with allergic rhinitis.3 Eosinophils are considered to
be the major inflammatory cells in allergic rhinitis,
since eosinophils release proinflammatory mediators,
such as leukotriene C4 and platelet-activating factor
which increase permeability and are a potent chemo-
tactic factor for eosinophils.4 Eosinophils also pro-
duce a number of potent, highly positively charged
proteins which are toxic to the human respiratory epi-
thelium.5 Peroxisome proliferators-activated receptor-
γ (PPAR-γ), a member of the nuclear hormone recep-
tor superfamily, has a critical role in adipogenesis,
glucose metabolism.6 One group of synthetic PPAR-γ
agonistic ligands are glitazones. Glitazones are drugs
used in the treatment of diabetic patients.7 One of the
natural ligands for PPAR-γ is 15-deoxy-∆-
prostaglandin J2 (15d-PGJ2), an arachidonic acid me-
tabolite.8 Furthermore, PPAR-γ also plays an impor-
tant role in the control of the inflammatory response
acting on T cells,9 macrophages,10 dendritic cells,11
mast cells,12 and eosinophils.13,14 In monocytes and
macrophages PPAR-γ agonists inhibit the expression
of proinflamatory cytokines, such as TNF-α, IL-1β,
and IL-6.10 In human cultured mast cells (HCMC)
PPAR-γ agonists attenuated the production of
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granulocyte-macrophage colony-stimulating factor by
anti-IgE-stimulated HCMC.12 It was reported that ad-
ministration of PPAR-γ agonist inhibited the develop-
ment of allergic inflammation, including pulmonary
eosinophilia, airway hyperresponsiveness (AHR), cy-
tokine production, GATA-3 expression, and the se-
rum level of antigen-specific IgE in a murine model of
asthma.13,15 In addition, PPAR-γ is expressed in air-
way epithelium and smooth muscle, and PPAR-γ ago-
nist nebulization reduces airway remodeling.16
However, the effects of PPAR-γ on allergic rhinitis,
upper airway IgE-mediated inflammation have not
been clarified. The present study was aimed at inves-
tigating the effect of PPAR-γ agonist on nasal symp-
toms and eosinophils accumulations in the nasal mu-
cosa by using a murine allergic rhinitis model. Fur-
thermore, we examined the expression of PPAR-γ in
the nasal mucosa in mice.
METHODS
MURINE ALLERGIC RHINITIS MODEL
Because the complete inactivation of the PPAR-γ gene
leads to embryonic lethality, the PPAR-γ agonist, cigli-
tazone, was used to investigate the potential role of
PPAR-γ as a regulator of airway inflammation. Female
6―8 week-old BALBc mice, housed under pathogen-
free conditions, were sensitized by means of intrape-
ritoneal injection of 50 μg ovalbumin (OVA) (Sigma,
Steinheim, Germany) in 100 μl of alum (Pierce, Rock-
ford, USA) or received alum only and were chal-
lenged intranasally (i.n.), on day 23 to 27 with OVA,
20 μl of PBS containing 500 μg of OVA. Ciglitazone
(20 mgkg in 1% carboxymethylcellulose, Sigma) was
administered orally 6 hours before the OVA chal-
lenge on day 22 to 26. Serum was collected on day 28.
Mice were killed 12 hours after i.n. provocation with
OVA. The Institutional Review Board of the Akita
University School of Medicine approved all animal ex-
periments.
CLINICAL SYMPTOMS
Nasal symptoms were evaluated by counting the
number of sneezes and nasal rubs that occurred in
the 10 minutes after OVA i.n. provocation, by the
same dose of OVA as given during the daily chal-
lenge on day 27. 12 hours after intranasal provocation
on day 27, nasal histamine responsiveness (NHR)
was measured. It was measured by determining the
limiting concentration of histamine that caused
sneezes and rubs. Nasal challenges with 20 μl of seri-
ally diluted histamine solution were administered.
SERUM OVA-SPECIFIC IgE LEVEL
Serum anti-OVA IgE concentration was measured by
ELISA, using a specific ELISA kit. (Shibayagi,
Gunma, Japan)
HISTOLOGY
Nasal mucosa samples were fixed with formalin for 3
days at 4℃. After dehydration with ethanol, they
were embedded in paraffin. The embedded tissues
were cut into 3 μm thin sections using a microtome,
and stained with Eosinostain-Hansel (Torii, Tokyo,
Japan). To evaluate eosinophilic infiltration in the na-
sal mucosa, we counted the number of eosinophils,
which was the same part of the coronal slice of the
nasal mucosa.
IMMUNOHISTOCHEMISTRY
Nasal mucosa samples were fixed with Immuno-
histofix (Intertiles, Brussels, Belgium) for 3 days at
4℃. After dehydration in graded alcohol baths em-
bedded in Immunohistowax (Intertiles), the embed-
ded tissues were cut into 3 μm thin sections using a
microtome. Dewaxed and TBS-washed sections were
incubated with 3% H2O2 in methanol for 20 minutes to
block endogenous peroxidases. Sections were
washed with TBS, and incubated with 5% skimmed
milk in TBS for 20 minutes to block endogenous per-
oxidases. And then, sections were incubated with rab-
bit anti-human PPAR-γ (SC-7196: Santa Cruz Biotech-
nology, CA, USA) for 2 hours at room temperature.
After washing, sections were incubated with ENVI-
SION+ RabbitHRP (K4002: Dako, Denmark) for 30
minutes at room temperature. Sections were counter-
stained with hematoxilin.
CYTOKINES IN SPLEEN TISSUE MEASURE-
MENT
Spleen samples were homogenized in 300 μl of buffer
containing 1% NP-40, 150 mM NaCl, 50 mM Hepes,
PMSF, and Complete protease inhibitor cocktail. IL-5,
IL-13, IFN-γ were measured using specific ELISA
kits. (ELM-IFNgamma-001, ELM-IL5-001, ELM-IL13-
001, RayBiotech, GA, USA)
STATISTICAL ANALYSIS
Values were expressed as means± SEMs. Data was
compared by using the unpaired t test. A P value of
less than 0.05 was considered significant.
RESULTS
CLINICAL SYMPTOMS
The number of nasal rubs after the OVA challenge in
the OVA-sensitized group was significantly higher
than that in the unsensitized group. Administration of
ciglitazone decreased the number of nasal rubs sig-
nificantly (Fig.1A). The number of sneezes after the
OVA challenge in the OVA-sensitized group was sig-
nificantly higher than the number in the unsensitized
group. Administration of ciglitazone decreased the
number of sneezes (not statistically significant;
Fig.1B). NHR in the OVA-sensitized group was sig-
nificantly higher than the NHR in the unsensitized
group. Administration of ciglitazone decreased the
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Fig. 1 Clinical symptoms in the unsensitized (control), the OVA-sensitized (OVA), and the ciglitazone ad-
ministrated mice (Cigli.). A: The number of nasal rubs that occured in the 10 minutes after the OVA i.n. 
provocation. B: The number of sneezes that occured in the 10 minutes after the OVA i.n. provocation. C: 
NHR is represented by the limiting concentration of histamine that caused sneezes and rubs.
NHR significantly (Fig.1C).
OVA ANTIGEN SPECIFIC SERUM IgE ANTIBODY
LEVEL
Serum levels of OVA-specific IgE in the OVA-
sensitized group were significantly higher than that
in the unsensitized group. Administration of ciglita-
zone significantly decreased the serum levels of OVA-
specific IgE (Fig.2A).
CYTOKINES IN SPLEEN TISSUE MEASURE-
MENT
IL-5 levels in the spleen tissue in the OVA-sensitized
group were significantly higher than the IL-5 levels in
the OVA-unsensitized group. Administration of cigli-
tazone significantly decreased the IL-5 levels in the
spleen (Fig.2B). IL-13 levels in the spleen tissue in
the OVA-sensitized group were also significantly
higher than that in the OVA-unsensitized group. Ad-
ministration of ciglitazone decreased IL-13 levels in
the spleen (not statistically significant; Fig.2C). IFN-γ
levels in the spleen tissue brought about no signifi-
cant differences in the all 3 groups (Fig.2D).
EOSINOPHILS INFILTRATION IN NASAL MU-
COSA
In the OVA-unsensitized mice, few eosinophils infil-
trated into the submucosa (Fig.3A). On the other
hand, many eosinophils infiltrated into the submu-
cosa in the OVA-sensitized mice (Fig.3B). In the
ciglitazone-administered mice, eosonophilic infiltra-
tion was decreased (Fig.3C). The number of eosino-
phils in the nasal mucosa was counted to evaluate
eosinophilic infiltration. The number of eosinophils of
nasal mucosa in the OVA-sensitized group was sig-
nificantly higher than that in OVA-unsensitized
group. Administration of ciglitazone significantly de-
creased eosinophil infiltration (Fig.4).
PPAR-γ EXPRESSION IN NASAL MUCOSA
Immunohistochemistry of nasal mucosa sections in
the OVA-sensitized mice revealed that PPAR-γ was
expressed in infiltrated cells in the submucosa and
epithelial cells (Fig.5B). Serial slices of each section
were stained by the eosinostain, and it was shown
that the cells infiltrated into the submucosa were
eosinophils (Fig.5C). On the other hand, PPAR-γ was
not expressed in the OVA-unsensitized mice.
80
60
40
20
0
－20
－15
－10
－5
0
5
N
um
be
r 
of
 r
ub
s
A
N
H
R
 (
lo
g1
0)
Control
C
P ＜ 0.05
P ＜ 0.05 P ＜ 0.05
P ＜ 0.05
OVA Cigli.
Control OVA Cigli.
20
15
10
5
0
N
um
be
r 
of
 s
ne
ez
es
B
Control
P ＜ 0.05
OVA Cigli.
Fukui N et al.
250 Allergology International Vol 58, No2, 2009 www.jsaweb.jp
Fig. 2 OVA-specific serum IgE levels and cytokine levels in spleen tissues in the unsensitized (control), 
the OVA-sensitized (OVA), and the ciglitazone administrated mice (Cigli.). A: OVA-specific serum IgE 
levels. B: IL-5 levels of spleen tissues. C: IL-13 levels of spleen tissues. D: IFN-γ levels of spleen tissues.
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Fig. 3 Nasal mucosa stained with Eosinostain-Hansel. A: control; OVA-unsensitized 
mice. B: OVA; OVA-sensitized mice. Many eosinophils infiltrated into the submucosa. Ar-
rows indicate eosinophils. C: Cigli.; Ciglitazone administration decreased eosinophilic 
infiltrations.
Control OVA Cigli.
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DISCUSSION
Allergic rhinitis is characterized by a two-phase aller-
gic reaction. In the early-phase inflammatory re-
sponse allergen-IgE dependent activation of mast
cells and basophils results in the production of phar-
macologically active mediators such as histamine,
prostaglandins, leukotrienes, and cytokines which
produce sneezing, rhinorrhea, and itching. The late-
phase response begins 2 to 4 hours following allergen
exposure at which point inflammatory cells, including
eosinophils, basophils, and T cells, infiltrate the local
tissue. Recruitment of inflammatory cells results in
further release of histamine and leukotrienes, as well
PPAR-γ Regulates Allergic Rhinitis
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Fig. 4 The number of eosinophils of nasal mucosa in the 
unsensitized (control), the OVA-sensitized (OVA), and the ci-
glitazone administrated mice (Cigli.) (original magnification, 
400×). Administration of ciglitazone significantly decreased 
eosinophils infiltration.
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Fig. 5 PPAR-γ expression in the nasal mucosa. A: OVA-sensitized mouse with control 
antibody. B: OVA-sensitized mouse with anti- PPAR-γ. C: OVA-sensitized mouse with 
Eosinostain-Hansel (original magnification, 400×). Arows indicate eosinophils, PPAR-γ 
was expressed in eosinophils and epithelial cels in the nasal mucosa.
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as other compounds including proinflamatory cytoki-
nes and chemokines, sustaining the allergic response
and promoting the late phase response.17 We have
demonstrated, in a murine allergic rhinitis model,
that oral administration of PPAR-γ agonist reduced
IgE production, nasal symptoms, NHR, eosinophils
accumulation in nasal mucosa, and that PPAR-γ ex-
pressed itself in eosinophils and airway epithelium in
nasal mucosa. According to the parameters (IgE pro-
duction and NHR) measured, this inhibitory effect
was totally abrogated by co-administration of
GW9662 a PPAR-γ antagonist (data not shown), thus
indicating that most ciglitazone-mediated effects may
occur through PPAR-γ stimulation in this model. Our
data shows that PPAR-γ regulates not only the early-
phase inflammatory response but also the late-phase
response. It has been shown that HCMC and human
basophilic cells express PPAR-γ and PPAR-γ ligands,
15-d-PGJ2 and troglitazone suppressed cytokine pro-
duction and histamine release.12,18 PPAR-γ was also
expressed in eosinophils.13,14 Their activation inhibits
chemotaxis and antibody-dependent cellular cytotox-
icity. In contrast to these findings, a recent study re-
vealed that 15d-PGJ2 appears to possess not only anti-
inflammatory activities but also a proinflamatory po-
tential depending on its concentration. At low concen-
trations, 15d-PGJ2 enhances eotaxin-induced chemo-
taxis in eosinophils through its ligation with PPAR-
γ.19 15d-PGJ2 binds two receptors, PPAR-γ and
CRTH2, which are both expressed on eosinophils in
Fukui N et al.
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allergic inflammation.20 Further investigation will be
required to reveal the role of PPAR-γ in eosinophils.
Airway epithelial cells constitutively express PPAR-γ,
mRNA, and protein and PPAR-γ agonists inhibit the
cytokine-mediated induction of inflammatory media-
tors. Furthermore IL-4 treatment significantly
upregulated PPAR-γ expression in airway epithelial
cells.21 This enhanced PPAR-γ expression may sup-
port our results that PPAR-γ expressed airway epithe-
lium in nasal mucosa in OVA-sensitized mice due to
the development of a Th2 response but did not ex-
press itself in control mice. There are numerous stud-
ies about PPAR-γ and inflammation, but the studies
about PPAR-γ and airway inflammation were limited.
In a previous study about PPAR-γ and lower airway in-
flammation, it was demonstrated in a murine model
of asthma, that PPAR-γ agonists decrease antigen-
induced AHR, pulmonary eosinophilia, cytokine pro-
duction, and GATA-3 expression as well as serum lev-
els of antigen-specific IgE. Furthermore, PPAR-γ is
expressed in airway epithelium and smooth muscle
on antigen challenge and PPAR-γ agonist nebulization
reduced airway remodeling including collagen depo-
sition and production of TGF-β. Similar findings have
been reported by others.15 In a human sample, PPAR-
γ is augmented in the bronchial submucosa, the air-
way epithelium, and the smooth muscle of asthmatic
patients, as compared with control subjects.22 These
studies indicated that PPAR-γ may decrease AHR
regulating eosinophils, T cells, and airway epithelial
cells in lower airway inflammation.
We showed that oral administration of PPAR-γ ago-
nist reduced IgE production, nasal symptoms, NHR,
eosinophils accumulation in nasal mucosa, and that
PPAR-γ expressed itself in eosinophils and airway epi-
thelium in nasal mucosa in a murine model of allergic
rhinitis. Considered together, activation of PPAR-γ in
this model appears to regulate upper airway allergic
inflammation by down regulating IL-5 production act-
ing on epithelial cells and eosinophils.
In a human sample study of allergic rhinitis, the ex-
pression levels of PPAR-γ, m-RNA, and protein in the
nasal mucosa was significantly higher in patients with
perennial allergic rhinitis compared with the con-
trol.23 In another group, no differences in the expres-
sion of PPARs were obtained in nasal biopsies from
both patients with seasonal allergic rhinitis and
healthy volunteers.24 These studies suggested that
PPAR-γ which expresses nasal mucosa, eosinophils,
and other inflammatory cells might regulate upper
airway allergic inflammation in humans.
Finally, we have demonstrated that PPAR-γ was ex-
pressed in eosinophils and epithelial cells in nasal
mucosa and that the oral administration of ciglitazone
is effective at inhibiting eosinophil accumulations in
nasal mucosa and nasal symptoms. Our results pro-
vide for the therapeutic potential of the PPAR-γ ago-
nist for allergic rhinitis.
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